A group of autism researchers and advocates have formed a new, independent advisory group with a name that’s so similar to a federal autism group, you can’t assume it’s a coincidence. The Independent Autism Coordinating Committee (I-ACC) will hold its first meeting on March 19, the same day that its federally funded doppelganger, the […]
Autism researchers form new group, rebuke Kennedy Read More »
PARIS — Doses of interleukin (IL)-17 and IL-23 inhibitors were safely reduced in people with plaque psoriasis who had “very stable low disease activity”; it was reported during a late-breaking news session last week at the European Academy of Dermatology and Venereology (EADV) 2025 Congress. “We showed a stepwise dose reduction of IL-17 and IL-23 inhibitors is noninferior
Meds Can Be Reduced by Half in Some Plaque Psoriasis Cases Read More »
Christine Kilgore December 26, 2025 High induction doses of risankizumab — at double and quadruple the approved 150 mg dose — produced rapid and durable skin clearance in patients with moderate-to-severe plaque psoriasis while significantly reducing tissue resident memory T cells (TRM) in the just-published phase 2 KNOCKOUT study led by Andrew Blauvelt, MD, MBA. The small study randomized 20 patients to either
Study team members Stephan Ramos, Seung Kim, and Preksha Bhagchandani – credit, Steve Fisch, Stanford UniversityIn an experiment that exceeded scientists’ expectations, mice had their type-1 diabetes cured through a double-transplant method. Additionally, there was no host rejection of one one of the two types of transplanted cells, and the immune system didn’t attack the
Stanford Cures Type-1 Diabetes in Mice Without Insulin or Immune-Suppression Read More »
TOPLINE: Biologic therapies demonstrated comparable safety to conventional systemic agents in patients with psoriasis who had active cancer or recent cancer history, with similar progression and recurrence rates. METHODOLOGY: To address the limited data available on the safety of biologics in patients with cancer, researchers conducted a retrospective, active comparator-controlled surveillance study of 333 treatment
Are Biologics Safe in Patients With Psoriasis and Cancer? Read More »
Medscape Dermatology asked Steven R. Feldman, MD, PhD, professor of dermatology at Wake Forest University School of Medicine, Winston-Salem, North Carolina, to share his expertise on the impact biosimilar versions of FDA-approved biologics are having in dermatology. How do you characterize the availability of biosimilars for treating psoriasis, atopic dermatitis, and other skin diseases? Can you provide
What About Biosimilars in Dermatology? Q&A With Steven R. Feldman, MD Read More »
Damian McNamara, MA February 11, 2026It’s rare that terms such as “life changing,” “tremendous advance,” or “a difference of night and day” describe an evolving class of therapeutics without sounding like hyperbole. But in the case of biologics in dermatology, these assessments might be spot on. In fact, these agents continue to revolutionize patient care,
Biologics Continue to Transform Dermatology, With Safer and More Effective Care – Read More »
by Angela Yeager, Oregon Health & Science University edited by Lisa Lock, reviewed by Andrew Zinin Editors’ notes The GIST Add as preferred source Credit: Pixabay/CC0 Public Domain Oregon Health & Science University researchers have found that certain nerves that play an integral role in the body’s “fight or flight” stress response can support pancreatic tumor growth. These
Study finds stress-related nerves may fuel pancreatic cancer growth Read More »
Implications for the treatment of diabetes Peer-Reviewed PublicationVrije Universiteit Brussel The beta cells in our pancreas act as highly sensitive sensors that constantly measure the amount of sugar in our blood. As soon as we eat something and the sugar level rises, the beta cells produce insulin to help the body process the sugar properly.
Iron deficiency blocks the growth of young pancreatic cells Read More »
Peer-Reviewed PublicationUniversity of Bath video: Professor Jody Mason, from the University of Bath and CEO of Revolver Therapeutics, explains the new technology. view more Credit: University of Bath Researchers at the University of Bath have developed a new technology that uses bacteria to build, chemically stabilise, and test millions of potential drug molecules inside living cells,
Chemically ‘stapled’ peptides used to target difficult-to-treat cancers Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866